BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/20/2023 4:48:38 PM | Browse: 340 | Download: 1253
 |
Received |
|
2023-06-13 18:32 |
|
Peer-Review Started |
|
2023-06-13 18:33 |
|
First Decision by Editorial Office Director |
|
2023-08-08 03:51 |
|
Return for Revision |
|
2023-08-08 03:51 |
|
Revised |
|
2023-08-17 02:30 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2023-08-23 02:48 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2023-08-23 07:56 |
|
Articles in Press |
|
2023-08-23 07:56 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2023-08-31 09:34 |
|
Publish the Manuscript Online |
|
2023-09-20 16:48 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Case Report |
| Article Title |
Combination therapy with toripalimab and anlotinib in advanced esophageal squamous cell carcinoma: A case report
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Si-Cong Chen, Dong-Heng Ma and Jia-Jian Zhong |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Jia-Jian Zhong, MM, Surgeon, Hepatobiliary and Pancreatic Surgery, Huazhong University of Science and Technology Union Shenzhen Hospital, No. 89 Taoyuan Road, Nanshan District, Shenzhen 518052, Guangdong Province, China. jjzhong11@163.com |
| Key Words |
Esophageal squamous cell carcinoma; Toripalimab; Anlotinib; Complete response; Case report |
| Core Tip |
Toripalimab and anlotinib have emerged as second-line or above-line treatment options for advanced esophageal cancer. However, their objective remission rates and progression-free survival are low when used alone. We report a case of complete response after combination therapy of toripalimab and anlotinib in a patient newly diagnosed with advanced esophageal squamous cell carcinoma. The patient was in remission for 14 mo. Hence, toripalimab combined with anlotinib may be a new and effective treatment for advanced unresectable esophageal squamous cell cancer. |
| Publish Date |
2023-09-20 16:48 |
| Citation |
Chen SC, Ma DH, Zhong JJ. Combination therapy with toripalimab and anlotinib in advanced esophageal squamous cell carcinoma: A case report. World J Clin Cases 2023; 11(27): 6579-6586 |
| URL |
https://www.wjgnet.com/2307-8960/full/v11/i27/6579.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v11.i27.6579 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
